Regeneron Z Score
REGN  Stock  USD 643.29 14.58 2.32% 
Regeneron  Z Score 
Regeneron Z Score Analysis
Regeneron Pharmaceuticals' ZScore is a simple linear, multifactor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..2015  2016  2021  2022 (projected)  
Enterprise Value  56.23 B  38.18 B  34.36 B  37.07 B 
Average Equity  3.32 B  4.2 B  3.78 B  4.07 B 
Z Score  =  Sum Of   5 Factors 
Current Regeneron Pharmaceuticals Z Score  19.7 
Most of Regeneron Pharmaceuticals' fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Regeneron Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
 
 
 
 

Regeneron Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Regeneron Pharmaceuticals is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Z Score. Since Regeneron Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Regeneron Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Regeneron Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate ZScore one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. ZScore can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with ZScores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a socalled 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Compare to competition 
Based on the company's disclosures, Regeneron Pharmaceuticals has a Z Score of 19.7. This is 191.85% higher than that of the Healthcare sector and notably higher than that of the Biotechnology industry. The z score for all United States stocks is 125.92% lower than that of the firm.
Regeneron Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Regeneron Pharmaceuticals' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Regeneron Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Regeneron Pharmaceuticals by comparing valuation metrics of similar companies.Regeneron Pharmaceuticals is rated below average in z score category among related companies.
Regeneron Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Regeneron Pharmaceuticals from analyzing Regeneron Pharmaceuticals' financial statements. These drivers represent accounts that assess Regeneron Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Regeneron Pharmaceuticals' important valuation drivers and their relationship over time.
2017  2018  2019  2020  2021  2022 (projected)  
Net Income Per Employee  193.31 K  330.32 K  261.21 K  384.04 K  778.87 K  840.36 K  
Revenue Per Employee  947.13 K  906.87 K  970.79 K  928.85 K  1.55 M  1.67 M  
Earnings Before Interest Taxes and Depreciation Amortization EBITDA  2.25 B  2.73 B  2.66 B  4.1 B  9.66 B  10.43 B 
Regeneron Fundamentals
Return On Equity  49.75 %  
Return On Asset  25.84 %  
Profit Margin  48.06 %  
Operating Margin  57.03 %  
Current Valuation  58.32 B  
Shares Outstanding  105.72 M  
Shares Owned by Insiders  2.69 %  
Shares Owned by Institutions  88.20 %  
Number of Shares Shorted  2.86 M  
Price to Earning  9.95 X  
Price to Book  3.80 X  
Price to Sales  4.05 X  
Revenue  16.51 B  
Gross Profit  10.73 B  
EBITDA  9.41 B  
Net Income  7.93 B  
Cash and Equivalents  7.05 B  
Cash per Share  65.44 X  
Total Debt  2.7 B  
Debt to Equity  0.14 %  
Current Ratio  4.76 X  
Book Value Per Share  163.52 X  
Cash Flow from Operations  8.51 B  
Short Ratio  4.42 X  
Earnings Per Share  62.53 X  
Price to Earnings To Growth  (0.66) X  
Number of Employees  10.49 K  
Beta  0.31  
Market Capitalization  66.91 B  
Total Asset  5.61 B  
Retained Earnings  1.7 B  
Working Capital  2.1 B  
Current Asset  2.92 B  
Current Liabilities  811.16 M  
Z Score  19.7 
About Regeneron Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Regeneron Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regeneron Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regeneron Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10492 people.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Regeneron Pharmaceuticals without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.riskadjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Fundamentals Comparison Now
Fundamentals ComparisonCompare fundamentals across multiple equities to find investing opportunities 
All Next  Launch Module 
Currently Active Assets on Macroaxis
Additionally, take a look at Regeneron Pharmaceuticals Piotroski F Score and Regeneron Pharmaceuticals Valuation analysis. Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and riskadjusted market performance.
Complementary Tools for Regeneron Stock analysis
When running Regeneron Pharmaceuticals price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio SuggestionGet suggestions outside of your existing asset allocation including your own model portfolios  Go  
Portfolio VolatilityCheck portfolio volatility and analyze historical return density to properly model market risk  Go  
Financial WidgetsEasily integrated Macroaxis content with over 30 different plugandplay financial widgets  Go  
Premium StoriesFollow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope  Go  
Volatility AnalysisGet historical volatility and risk analysis based on latest market data  Go  
Equity AnalysisResearch over 250,000 global equities including funds, stocks and ETFs to find investment opportunities  Go  
Positions RatingsDetermine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and riskadjusted market performance  Go 
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Regeneron Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.